Navane (thiothixene) is a small molecule pharmaceutical. Thiothixene was first approved as Navane on 1982-01-01. It is used to treat psychotic disorders, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. In addition, it is known to target histamine H1 receptor.
|Indication||psychotic disorders, schizophrenia, schizophrenia spectrum and other psychotic disorders|
|Drug Class||Typical antipsychotic|